Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161844 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C9ALOX15NFKB1 | |
| SCHEMBL22147348 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C9ALOX15NFKB1 | |
| SCHEMBL13106903 | 0.87 | RAF1 (0.42) | MAPK1ALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL162151 | 0.83 | LMNA (0.52) | CYP3A4CYP1A2MAPK1HIF1AABCC9 | |
| SCHEMBL162150 | 0.83 | LMNA (0.52) | CYP3A4CYP1A2MAPK1HIF1AABCC9 | |
| SCHEMBL13105581 | 0.82 | IDO1 (0.46) | CYP3A4MAPK1HSD17B10ABCC9ALDH1A1 | |
| SCHEMBL16471293 | 0.82 | IDO1 (0.46) | CYP3A4MAPK1HSD17B10ABCC9ALDH1A1 | |
| SCHEMBL15881324 | 0.82 | SMARCA2 (0.43) | KMT2AMEN1 | |
| SCHEMBL19069839 | 0.81 | ALDH1A1 (0.41) | CYP3A4CYP1A2CYP2C19ALDH1A1LMNA | |
| SCHEMBL16013312 | 0.81 | SMARCA2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20210395222-A1 | Fused Bicyclic Heterocycles as Therapeutic Agents | NEW YORK UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| EP-3856735-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | New York University (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020073031-A1 | FUSED BICYCLIC HETEROCYCLES AS THEREAPEUTIC AGENTS | NEW YORK UNIVERSITY (US) | 2020-04-09 | — | — | WO | disclosed |
| US-9676721-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2611778-B1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | disclosed |
| EP-2611778-A1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012031199-A1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CYP3A4 3993/4885CYP1A2 3487/4885CYP2C9 4352/4885 |
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NAMPT, NQO1, NAPRT | CYP3A4 4662/4885CYP1A2 4465/4885CYP2C9 4716/4885 |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CYP3A4 2406/4885CYP1A2 2312/4885CYP2C9 2114/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CYP3A4 3993/4885CYP1A2 3487/4885CYP2C9 4352/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | CYP3A4 3993/4885CYP1A2 3487/4885CYP2C9 4352/4885 |
| US-20210395222-A1 | Fused Bicyclic Heterocycles as Therapeutic Agents | NAMPT, NQO1, NAPRT | CYP3A4 4662/4885CYP1A2 4465/4885CYP2C9 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.